AUSTIN, Texas--(BUSINESS WIRE)--Caisson Biotech, LLC has engaged Pickwick Capital Partners, LLC (member FINRA/SIPC) to assist in the sale of the HEPtune® drug-delivery platform. The proprietary platform centers on the use of a naturally occurring sugar polymer, heparosan, which is produced by the body and is naturally biodegradable. The platform includes a robust US and international patent portfolio and has been proven in hemophilia. Additional opportunities are potentially available in a range of established, billion-dollar biologic therapeutics markets, as well as for improved delivery of small molecules via nanocarriers.
“The sale is designed to accelerate broad industry adoption of heparosan and deliver its clinical benefits to the maximum number of patients possible,” Caisson said.
“Caisson’s HEPtune® platform has been demonstrated to improve proteolytic activity and half-life for hemophilia Factor VII compared to unconjugated FVII or FVII conjugated with polyethylene glycol (PEG). Additionally, HEPtune enables new patent protection for drug conjugates, can lower costs, and reduce the growing concern of immunogenicity with PEG conjugates,” said Paul Bundschuh, a managing director at Pickwick Capital Partners. “Many therapeutic protein market opportunities exist that could benefit from HEPtune. Pickwick is excited to leverage our life sciences/biotech team of experienced bankers and subject-matter experts to help Caisson find the ideal buyer/s.” For questions regarding the sale of the HEPtune platform, contact: Paul Bundschuh, email@example.com.
HEPtune was developed by Caisson and Dr. Paul DeAngelis, at the University of Oklahoma. Visit: www.caissonbiotech.com
Caisson is funded and managed by Austin-based Emergent Technologies, Inc. Visit: www.emergenttechnologies.com
Pickwick Capital Partners, LLC, helps innovative companies in the lower middle-market achieve their strategic objectives though M&A and capital raising. Visit: www.pickwickcapital.com
The above, which should be read in conjunction with additional materials to be provided by the company, has been provided to the recipients for basic information purposes only. Past performance is not indicative of future results. The information contained in this summary is not complete and is being provided solely to solicit interest in receiving additional information. An investment in the company has significant risks. Investors are advised to review the risk factors in the Confidential Information Memorandum. The above does not constitute an offer to sell, or solicitation to buy, any securities or assets of the company.